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Background: The most common human papillomavirus (HPV) genotypes isolated from cervical cancer in select
African countries are HPV-16, HPV-18, HPV-35, and HPV-45, but the most common genotypes in Zambia are
unknown. The overall objective of this study was to assess the potential impact of current HPV vaccines in
preventing cervical cancer in Zambia, by determining the combined prevalence of HPV-16 and/or HPV-18 in
invasive cervical cancer (ICC) and high-grade pre-cancer [cervical intraepithelial neoplasia 2 or 3 (CIN2/3)] cases.
Findings: We compared DNA extraction techniques to determine which assay performs well in the Zambian
context, where unbuffered formalin is used to fix specimens. We then tested specimens with the Abbott RealTime
High-Risk HPV test to estimate the prevalence of HPV-16/18 in formalin-fixed, paraffin-embedded ICC and CIN2/3
specimens. DNA extraction using heat (without xylene) was more successful than xylene-based extraction. Over
80% of specimens tested using heat extraction and the Abbott RealTime HPV test were positive for HPV. HPV-16
and/or HPV-18 were identified in 65/93 (69.9%) ICC specimens positive for HPV and in 38/65 (58.5%) CIN2/3
specimens positive for HPV.
Conclusions: To our knowledge this is the first report to identify HPV genotypes in cervical cancers in Zambia. A
combined HPV-16/18 prevalence of 69.9% in ICC specimens suggests that current vaccines will be highly protective
against cervical cancer in Zambia.
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Background
Cervical cancer is the second most common cancer in
women worldwide [1] and is the most common female
malignancy referred to the University Teaching Hospital
(UTH) in Lusaka [2]. Human papillomaviruses (HPVs)
are responsible for over 90% of cervical cancers [3,4].
Fifteen HPV types have been associated with cervical
cancer [5] and are collectively known as oncogenic or* Correspondence: bateman.allen@gmail.com
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unless otherwise stated.high-risk types. The two most common are HPV-16 and
HPV-18, which are associated with 60–70% of cervical
cancer worldwide [5]. HPV-16 and HPV-18 are the two
genotypes included in currently licensed HPV vaccines
(Cervarix® and Gardasil®). Cost-effectiveness modeling
estimates that HPV-16/18 vaccines can decrease the life-
time risk of cervical cancer in women in Central and
Eastern Africa by 36–45% [6]. However, these vaccines
can only prevent cervical cancer in areas where HPV-16
and HPV-18 are primary causes. The most common
genotypes isolated from cervical cancer in select African
countries are HPV-16, HPV-18, HPV-35, and HPV-45
[7,8], but common genotypes in Zambia are unknown.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Zambia reported a wide diversity of HPV genotypes [9,10],
generating concern that current HPV vaccines might not
have a large preventive effect in Zambia. However, most
pre-cancerous lesions do not develop into cancer, and to
determine if HPV-16 and HPV-18 cause invasive cervical
cancer (ICC) requires testing ICC specimens.
To assess the impact that current vaccines can have in
preventing cervical cancer in Zambia, we first compared
DNA extraction techniques to determine which performed
better in the Zambian context. We then estimated the
combined prevalence of HPV-16 and/or HPV-18 in
formalin-fixed, paraffin-embedded (FFPE) ICC and cervical
intraepithelial neoplasia 2 or 3 (CIN 2/3) specimens from
UTH. Our main outcomes were the percentages of speci-
mens positive for HPV-16 and/or HPV-18.
Methods
UTH and the adjacent Cancer Diseases Hospital in Lusaka
are the primary centers for cancer diagnosis and treatment
in Zambia. FFPE cervical specimens obtained during rou-
tine clinical care from 2007–2012 and stored at the UTH
Pathology Department were used for this study. Unbuf-
fered formalin is used for routine specimens at UTH,
which likely leads to more degraded DNA than if buffered
formalin were used [11]. Specimens were anonymized at
the time of sectioning, and HIV status was unavailable. To
minimize the potential for DNA contamination, gloves
were worn throughout the procedure, the microtome and
surrounding station were cleaned with DNAzap (Life
Technologies, Carlsbad, CA, USA) or bleach before begin-
ning work and between each specimen, and a new micro-
tome blade and pair of gloves was used for each block.
Non-HPV-containing specimens (spleen or liver) were
sectioned every 15 specimens and tested; all of these
controls were negative for HPV, as expected. The first and
last sections of each cervical specimen block were 3 μm
thick and were mounted on slides, stained with H&E, and
reviewed by a pathologist at UTH to confirm the diagno-
sis. The middle sections (n = 3 to 9, depending on the
tissue size) were 10 μm thick and were placed into 2.0 ml
Screw Cap Micro Tubes (Sarstedt, Nümbrecht, Germany)
and taken to the CIDRZ Central Laboratory for DNA
extraction and HPV testing.
We compared two extraction techniques: heat-
dependent and xylene-dependent. The heat extraction
technique was adapted from Steinau et al. [12]. To each
tube, 180 μl of ATL lysis buffer from a DNeasy Blood
and Tissue Kit (Qiagen, Valencia, CA) was added and
heated at 99°C for 30 minutes. Proteinase K (20 μl) was
added, tubes were incubated at 56°C with shaking at
1,000 rpm for 16 hours, 400 μl of Buffer AL:ethanol
mixture was added, and the DNA was further purified
with the Qiagen kit.The xylene extraction technique was adapted from
Kocjan et al. [13]. To each specimen, 1.2 ml xylene was
added, followed by vortexing and centrifugation at max-
imum speed for 5 minutes. The supernatant was removed,
1.6 ml of 100% ethanol was added to the pellet, followed
by vortexing and centrifugation for 5 minutes. The speci-
men was washed two additional times and the pellet was
air-dried for 15 minutes and resuspended in 180 μl of buf-
fer ATL from a QIAamp DNA Mini Kit (Qiagen). Protein-
ase K (20 μl) was added, samples were incubated overnight
at 56°C with shaking at 1,000 rpm, 200 μl of buffer AL was
added, and DNA was further purified with the Qiagen kit.
For both extraction techniques, DNA was recovered in a
single elution step with 110 μl of AE solution.
Nucleic acid concentrations were determined using a
Nanodrop ND-1000 spectrophotometer (Thermo Fisher
Scientific, Wilmington, DE, USA), and DNA extracts were
frozen at −80°C until further analysis.
Extracted DNA was tested using the Abbott RealTime
High Risk HPV assay (Abbott Laboratories, Abbott Park,
IL, USA), which uses real-time PCR to amplify and de-
tect 14 high-risk genotypes [14]. RealTime also differen-
tiates between HPV-16, HPV-18, and non-HPV16/18
genotypes (other high-risk). RealTime contains primers
and probes specific for the human β-globin gene, to moni-
tor DNA extraction and amplification. A cycle threshold
(Ct) value of <35 was considered positive for each of the
RealTime channels.
Data were entered into Microsoft Excel™ (Redmond, WA,
USA), cleaned with SAS™ version 9.2 (SAS Institute Inc.,
Cary, NC, USA), and analyzed using SAS™ and Open Epi
(www.openepi.com). p < 0.05 was considered significant.
Results
To determine the most effective DNA extraction tech-
nique, 27 FFPE specimens (aged 3–5 years old) were ex-
tracted using the two techniques. The mean nucleic acid
concentration (standard deviation) following heat extrac-
tion was 117.4 ng/μl (85.4 ng/μl), while that following
xylene extraction was 38.2 ng/μl (35.9 ng/μl) (p < 0.0001,
Wilcoxon signed-rank test).
The 27 FFPE specimens were tested with the RealTime
assay. RealTime successfully identified HPV in the vast
majority of specimens: one or more HPV was identified
in 23/27 with heat extraction and 21/27 with xylene
extraction (Table 1). In addition, heat extraction resulted
in lower Ct values than xylene extraction (Table 1). There-
fore, the remaining FFPE specimens were tested using
heat extraction.
Including the initial 27 specimens, 189 FFPE speci-
mens were tested, including 114 ICC (109 squamous cell
carcinoma and 5 adenocarcinoma) and 75 CIN 2/3. Of
114 ICC specimens tested, 88% were valid results (Table 2).
Of the valid ICC results, HPV was identified in 93 (93%),
Table 1 RealTime results and Ct values from DNA
extracted from ICC and CIN2/3 specimens using heat or
xylene treatment
Heat Xylene
RealTime result n n
Invalida 2 2
No HPV detected 2 4
Single HPV infection 18 19
Dual HPV infections 4 2









β-globin internal control 25 27.7 24 30.6 <0.001
HPV-16 14 23.8 12 25.3 0.349
HPV-18 3 26.3 3 29.9 0.222
other HR HPV 13 28.1 9 31.0 0.156
aβ-globin internal control was either negative or had a Ct count >35.
bStudent’s t-test.
Results represent three separate experiments of 9 specimens each (27 FFPE
specimens total; 17 ICC and 10 CIN 2/3). Ct values above 35 were excluded.
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ing specimens with multiple HPV genotypes identified,
52% of specimens were positive for HPV-16 and 25% were
positive for HPV-18; together, 65/93 (70%; 95% CI: 60%–
78%) were positive for HPV-16 and/or HPV-18 (Table 2).
Three (60%) of the adenocarcinoma specimens had valid
results; of these, HPV-16 and/or HPV-18 was identified in
2/3 (67%).
Of 75 CIN 2/3 specimens tested, 92% were valid
results (Table 2) and HPV was identified in 65/69 (94%),
including 48 single infections and 17 co-infections. Includ-
ing specimens with multiple HPV genotypes identified,Table 2 HPV results of ICC and CIN2/3 specimens tested






Total tested 114 -- 75 --
Total with valid resultsa 100 -- 69 --
Positive for any HPVb 93 -- 65 --
HPV-16 positive 48 51.6% (41.6–61.5) 36 55.4% (43.3–66.8)
HPV-18 positive 23 24.7% (17.1–34.4) 5 7.7% (3.3–16.8)
Other HR HPV
positive
38 40.9% (31.4–51.0) 43 66.2% (54.0–76.5)
HPV-16 and/or HPV-18
positive
65 69.9% (59.9–78.3) 38 58.5% (46.3–69.6)
aInvalid results mean the β-globin internal control was not reactive or had a Ct
value of >35.
bIncluding specimens with multiple HPV types identified. The number of
specimens that were positive for HPV was used as the denominator for
prevalence estimates.38/65 (59%; 95% CI: 46%–70%) of specimens were positive
for HPV-16 and/or HPV-18 (Table 2).
Discussion
To our knowledge this is the first report to identify HPV
genotypes in ICC in Zambia. A combined HPV-16/18
prevalence of 69.9% in ICC specimens suggests that
current vaccines will be protective against cervical can-
cer in Zambia, and that the proportion of ICC attribut-
able to HPV-16/18 in Zambia is similar to that in South
Africa, Kenya, and the overall worldwide proportion [5].
The combined HPV-16/18 prevalence in CIN 2/3 speci-
mens (58.5%) was lower than that in ICC specimens, but
the difference was not significant (p = 0.14, two-tailed chi-
square test). This is consistent with previous studies in
Zambia and South Africa that reported a wide diversity of
HPV types in pre-cancer samples [9,10]. The heat extrac-
tion technique performed better than the xylene extrac-
tion technique in our study, which is consistent with
previous studies that report that DNA extraction without
xylene is more successful than with xylene [12,15]. The
Abbott RealTime assay identified HPV in over 80% of
the specimens. The use of unbuffered formalin at UTH
likely means that the Abbott RealTime (which has a 150
base pair amplicon) or other assays with relatively short
amplicons will be most sensitive for identifying HPV in
this context.
Strengths of this study include the successful develop-
ment of assays to identify HPV from FFPE specimens in
the Zambian context and the ability to estimate the
impact of HPV vaccines on both pre-cancer and cancer.
Weaknesses include the relatively small number of spec-
imens sampled from a single referral center. However,
because UTH is the primary center for cancer diagnosis
and treatment in Zambia, we believe that our estimate
of the prevalence of HPV-16/18 in cervical cancers is
the best available for the country to date.
With an estimated 69.9% of ICC specimens at UTH
containing HPV-16 and/or HPV-18, current HPV vaccines
can have a substantial preventive impact on cervical cancer
in Zambia. These data provide a rationale to advocate for
delivery of HPV vaccines throughout Zambia. In addition,
the methods described here can be used to examine the
role of HPV in other cancers in Zambia, such as head and
neck cancers [16,17], and the combined prevalence of
HPV16/18 in ICC can be used to examine the effect of
HPV vaccines, by testing FFPE specimens in the future.
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